Acne ‐ Clinical acne score · aAdult women with PCOS
1 finding from 1 review
Body‐mass index (BMI) · aAdult women with PCOS
1 finding from 1 review
Hirsutism ‐ Clinical F‐G score · adolescent women with PCOS
1 finding from 1 review
Adverse events ‐ Severe · adolescent women with PCOS
It is very uncertain whether oral contraceptive pill (OCP) changes adverse events ‐ Severe compared with metformin combined with OCP (very low certainty).
1 finding from 1 review
Minor adverse events · adolescent women with PCOS
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improved menstrual pattern · adolescent women with PCOS
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Acne ‐ Visual analogue scale or Clinical acne score · adolescent women with PCOS
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Body‐mass index (BMI) · adolescent women with PCOS
1 finding from 1 review
Plaque control · Children or adolescents
One RCT reported superior plaque control with a gamified mobile health app versus a conventional method; no effect estimate or GRADE assessment was reported.
1 finding from 1 review
Significant improvement in disability within 6 weeks · people with CIDP
Intravenous immunoglobulin showed no clear difference in significant improvement in disability within 6 weeks compared with intravenous methylprednisolone (moderate certainty).
1 finding from 1 review
Change in mean disability score on Rankin scale · people with CIDP
1 finding from 1 review
Change in mean disability score at 24 weeks or later · people with CIDP
1 finding from 1 review
Serious adverse events · people with CIDP
Intravenous immunoglobulin showed no clear difference in serious adverse events compared with intravenous methylprednisolone (moderate certainty).
1 finding from 1 review
Mean daily rating of problem severity (lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Mean change in daily rating of functional impairment: reduction of productivity (lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Mean change in daily rating of functional impairment: social activities (lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Mean change in daily rating of functional impairment: relationship interference (lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Changes in Premenstrual Tension Scale scores (observer‐rated; lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Changes in Premenstrual Tension Scale scores (self‐rated; lower score is better) · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
1 finding from 1 review
Withdrawals due to adverse events · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
Drospirenone plus ethinylestradiol may leads to higher withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review